Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ITEOS THERAPEUTICS, INC.

(ITOS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

iTeos Therapeutics : GSK, Iteos Collaborate For EOS-448, Iteo To Get $625 Mln Upfront Payment

06/14/2021 | 07:05am EDT

June 14 (Reuters) - GlaxoSmithKline PLC:

* GLAXOSMITHKLINE PLC - GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448

* GSK - EOS-448 IS CURRENTLY IN PHASE I FOR ADVANCED SOLID TUMOURS WITH A RANDOMISED PD-1 COMBINATION STUDY PLANNED FOR 2022

* GSK - ITEOS TO RECEIVE A $625 MILLION UPFRONT PAYMENT IN ADDITION TO POTENTIAL MILESTONES, AND ROYALTY PAYMENTS ON EX-US SALES

* GSK -

* GSK - GSK AND ITEOS WILL CO-COMMERCIALISE AND SHARE PROFITS IN US

* GSK - GSK NOW HAS LEADING PORTFOLIO OF ANTIBODIES TARGETING CD226 AXIS - A KEY TARGET FOR NEXT-GENERATION IMMUNO-ONCOLOGY THERAPIES

* GSK - WITH THIS COLLABORATION GSK IS UNIQUELY POSITIONED WITH ACCESS TO ANTIBODIES THAT SYNERGISTICALLY TARGET ALL THREE KNOWN CD226 CHECKPOINTS

* GSK - ITEOS WILL BE ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $1.45 BILLION IN MILESTONE PAYMENTS, SHOULD EOS-448 PROGRAMME ACHIEVE CERTAIN MILESTONES

* GSK - WITHIN COLLABORATION, GSK AND ITEOS WILL SHARE RESPONSIBILITY AND COSTS FOR GLOBAL DEVELOPMENT OF EOS-448

* GSK - EXPECTS TO SUBMIT AN INVESTIGATIONAL NEW DRUG APPLICATION FOR GSK'562 (ANTI-PVRIG IN-LICENSED AS SRF-813 FROM SURFACE ONCOLOGY) BY MID-2022

* GSK - GSK AND ITEOS PLAN TO START COMBINATION STUDIES OF EOS-448 WITH DOSTARLIMAB IN 2022 Source text for Eikon: Further company coverage:


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.04% 1399.2 Delayed Quote.4.31%
ITEOS THERAPEUTICS, INC. -3.77% 23.51 Delayed Quote.-27.76%
All news about ITEOS THERAPEUTICS, INC.
07/08iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
GL
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) dropped from Russell 2000 Growth Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) dropped from Russell 3000 Growth Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to Russell Microcap Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) dropped from Russell 2500 Growth Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to Russell Microcap Value Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) dropped from Russell Small Cap Comp Gr..
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to Russell 3000E Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to Russell 3000E Value Index
CI
06/25ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) dropped from Russell 3000E Growth Inde..
CI
More news
Financials (USD)
Sales 2021 143 M - -
Net income 2021 -64,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,6x
Yield 2021 -
Capitalization 860 M 860 M -
Capi. / Sales 2021 6,03x
Capi. / Sales 2022 31,1x
Nbr of Employees 68
Free-Float 99,3%
Chart ITEOS THERAPEUTICS, INC.
Duration : Period :
iTeos Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ITEOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 24,43 $
Average target price 47,60 $
Spread / Average Target 94,8%
EPS Revisions
Managers and Directors
Michel Detheux President, Chief Executive Officer & Director
Matthew Gall Chief Financial Officer
David L. Hallal Chairman
Joanne Jenkins Lager Chief Medical Officer
Yvonne McGrath Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ITEOS THERAPEUTICS, INC.-27.76%860
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.32.49%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496